Study Reveals LDL Cholesterol Levels Exceed New Guidelines for Many U.S. Adults
A new study conducted by researchers at Mass General Brigham has found alarming statistics regarding LDL, or "bad" cholesterol levels among U.S. adults. The study reveals that nearly one in three adults without a history of heart disease, and almost four in five individuals who have previously experienced a heart attack, stroke, or other cardiovascular events, have LDL levels that surpass the goals set by the recently released 2026 American cholesterol guidelines. Furthermore, among those adults without heart disease who exceed the target LDL levels, about 76 percent are not receiving any cholesterol-lowering medication. These findings were published in the Journal of the American Medical Association (JAMA).
Lead author Shady Abohashem, an instructor in radiology at Harvard Medical School, emphasized the significant gap between the actual cholesterol levels in the U.S. population and the new guidelines, stating, "Heart disease remains a leading cause of death in this country, and a large share of heart attacks and strokes are preventable with medications we’ve had for decades. Yet many people who could benefit from treatment aren’t getting any. That is a missed opportunity at the scale of millions."
The 2026 guidelines from the American College of Cardiology and the American Heart Association introduced a new cardiovascular risk calculator and lowered LDL treatment goals, reflecting a growing body of evidence that suggests lower LDL levels are better for higher-risk patients. To assess how well the current U.S. population aligns with these updated treatment goals, Abohashem and his colleagues analyzed national data from approximately 2,300 adults aged 30 to 79 years, drawn from the National Health and Nutrition Examination Survey conducted between 2021 and 2023. This survey is federally administered and representative of roughly 178 million U.S. adults.
According to the updated guidelines, the recommended LDL levels vary based on an individual's cardiovascular risk. For adults at low risk, treatment is suggested when LDL levels reach 160 mg/dL or higher. Conversely, for those with established heart disease and a very high risk of future cardiovascular events, the target LDL level is set below 55 mg/dL.
The researchers discovered substantial discrepancies between the new LDL goals and the actual LDL levels among the population. Approximately one-third of U.S. adults without a history of cardiovascular events had LDL levels exceeding the new recommended goals; among this group, about 76 percent were not receiving any cholesterol-lowering medication. The gap widened significantly for individuals at higher cardiovascular risk, with around 83 percent exceeding the target LDL levels, and nearly half of this group not receiving any cholesterol-lowering treatment.
In the secondary prevention group, which includes adults with established heart disease, nearly four out of five individuals were above the recommended LDL goal. However, most of these individuals (about 62 percent) were already undergoing cholesterol-lowering therapy but still not achieving the lower targets, indicating a need for intensified treatment rather than initiating new therapies. The remaining 38 percent were not receiving any treatment at all.
Abohashem noted, "The good news is we know exactly what works, and the evidence behind these therapies is among the strongest in medicine. But these are really two different problems requiring two different solutions. In people without heart disease, most who are above target aren’t on any cholesterol-lowering medication at all, so the first step is simply starting treatment. Whereas in people who have already had a heart attack or stroke, most are already on a statin but still aren’t reaching the goal. For them, the answer isn’t starting therapy; it’s intensifying it. That might mean a stronger statin, adding a non-statin medication, or considering newer therapies. Recognizing that difference is essential to closing this gap."
The study authors highlight that falling short of LDL treatment goals is a persistent issue with various contributing factors, including limited access to newer medications, gaps in patient awareness, and structural barriers within the healthcare system. The data were collected prior to the publication of the 2026 guidelines, establishing a baseline to monitor progress as these guidelines are implemented in practice. Future research will investigate whether the gap narrows over time.
Abohashem concluded, "What we’re measuring here is a starting line, not a verdict. The new guidelines give us a clearer goal than we’ve ever had. For clinicians, that means re-evaluating patients against the updated targets. And for the public, the message is simpler: Know your LDL number, know your personal target, and if you don’t know either, ask your doctor."




